

Dysbiotic Co-Factors in Cervical Cancer. How the Microbiome Influences the Development of Cervical Intraepithelial Neoplasia (CIN)

Dysbiotische Co-Faktoren des Zervixkarzinoms. Der Einfluss des Mikrobioms auf die Entstehung zervikaler intraepithelialer Neoplasien (CIN)



Authors

Patrick Finzer^{1,2}, Volkmar Küppers³, Henrik Griesser⁴

Affiliations

- 1 dus.ana Düsseldorf Analytik, Praxis für medizinische Mikrobiologie und Laboratoriumsmedizin, Düsseldorf, Germany
- 2 Institut für Medizinische Mikrobiologie und Krankenhaus-hygiene, Heinrich-Heine Universität Düsseldorf, Düsseldorf, Germany
- 3 Zytologisches Labor, Dysplasie-Sprechstunde, Praxis für Frauenheilkunde & Geburtshilfe, Düsseldorf, Germany
- 4 Fachabteilung Pathologie und Zytodiagnostik, Labor Dr. Wisplinghoff, Köln, Germany

Key words

vaginal microbiome, HPV infection, CIN lesion

Schlüsselwörter

vaginales Mikrobiom, HPV-Infektion, CIN-Läsionen

received 9.12.2022

accepted after revision 20.2.2023

published online 4.5.2023

Bibliography

Geburtsh Frauenheilk 2023; 83: 1017–1021

DOI 10.1055/a-2044-0162

ISSN 0016-5751


© 2023. The Author(s).

This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (<https://creativecommons.org/licenses/by-nc-nd/4.0/>).

Georg Thieme Verlag KG, Rüdigerstraße 14,
70469 Stuttgart, Germany

Correspondence

Priv.-Doz. Dr. Dr. med. Patrick Finzer
dus.ana Düsseldorf Analytik, Praxis für medizinische
Mikrobiologie und Laboratoriumsmedizin
Immermannstraße 65 A
40479 Düsseldorf, Germany
gyn@dus-ana.de

 Deutsche Version unter:
<https://doi.org/10.1055/a-2044-0162>.

ABSTRACT

Human papillomavirus (HPV) infection is a necessary but not sufficient condition for the development of cervical cancer. The dysbiotic shift in the cervicovaginal microbiome appears to be a major co-factor in carcinogenesis. New analytical methods, such as next-generation sequencing (NGS), can be used to detect all of the vaginal microorganisms present and therefore identify individual therapeutic options. The relationship of bacterial vaginosis and carcinogenesis, as well as possible indications for the use of microbiome analysis, will be discussed.

ZUSAMMENFASSUNG

Die Infektion mit humanen Papillomaviren (HPV) ist für die Entstehung des Zervixkarzinoms eine notwendige, aber nicht hinreichende Bedingung. Die dysbiotische Verschiebung des zervikovaginalen Mikrobioms stellt offensichtlich einen wesentlichen Co-Faktor in der Karzinogenese dar. Neue Analysemethoden, wie das Next-Generation-Sequencing (NGS), erlauben die Bestimmung der Gesamtheit der vaginalen Mikroorganismen und damit die Ableitung individueller Therapieoptionen. Der Zusammenhang von bakterieller Vaginose und Karzinogenese sowie mögliche Indikationen für den Einsatz der Mikrobiom-Analyse werden diskutiert.

Introduction

Following the introduction of organized cancer screening for cervical carcinoma (“CC”) in 2020, a so-called co-test is performed on all women from the age of 35 every three years as part of cervical cancer screening. This means that a cervical smear sample is assessed cytologically and laboratory testing is performed for the genetic detection of the various high-risk types of human papillomavirus (HPV). Annual cytology screening continues to be performed in women under 35 years of age who are screened. In all women with cytological findings of confirmed or suspected high-grade dysplasia, a colposcopy is mandatory, irrespective of the HPV test result. In the majority of cases, tissue is removed from the cervix for histological examination [1].

Genetic material, particularly from high-risk types of HPV, is detectable in tumor tissue in almost all cases of cervical carcinoma. In this context, HPV-mediated carcinogenesis is mainly induced by the two viral oncoproteins E6 and E7. These oncoproteins drive the infected cells into an unregulated cell cycle and cause cell proliferation with the accumulation of genetic abnormalities in the epithelium [2].

However, HPV infection is not sufficient for the development of cervical cancer, because more than 90% of these infections are transient and resolve on their own (known as “clearance”) [3]. Of course, other factors are required for cancer or precancer to develop in the infected epithelium. An important prerequisite is a persistent HPV infection in the mucosal epithelia for many years. In recent years, the microbiome has been shown to be another important factor in the persistence of HPV infection and the development of cervical intraepithelial neoplasia (CIN).

It is therefore useful to test the vaginal microbiome – in addition to testing for HPV – if certain clinical questions or constellations of findings arise from the cervical cancer screening examination.

Bacterial Vaginosis Predisposes to HPV Infections and CIN Lesions

It has long been known that abnormal cytological findings are more common in women with disturbed vaginal flora [4], suggesting a link between bacterial vaginosis (BV) and the development of cervical cancer. In about half of cases, a disturbance of the vaginal environment leads to symptoms such as discharge that smells like ammonia and signs of inflammation, such as redness, itching, and a burning sensation. The vaginal pH is elevated and there are characteristic “clue cells” in the smear preparation [5]. BV is the most common vaginal disease in women of childbearing age and may be associated with gynecologic and obstetric complications, for example the spread of inflammation to the upper genital tract (“pelvic inflammatory disease [PID]”), cervicitis, premature birth, and chorioamnionitis.

Although scientific studies use different criteria to diagnose BV, several meta-analyses still show a clear association between the occurrence of bacterial vaginosis and CIN lesions [6, 7]. In addition,

it has also been confirmed that the prevalence of HPV is significantly higher in women with BV than in women without the disease [7].

New Technical Possibilities

It is not always easy to detect BV. In addition to microscopy, the cultivation of potential pathogens traditionally plays a major role in detecting possible pathogens with antibiotic testing (sensitivity testing) [8].

However, not all pathogens associated with BV can be grown in standard culture media. As a result, relevant microorganisms in bacterial vaginosis, such as *Atopobium* or *Mobiluncus*, usually cannot be detected. These pathogens must be detected by molecular genetic analysis, for example by means of polymerase chain reaction (“PCR”).

In addition, microorganisms are cultured in conventional medical microbiology with the aim of isolating, if possible, one or more potentially pathogenic agents from the microbial colony. The growth of other remaining microbes is deliberately suppressed by the selective media used. In the process, information about other pathogens, such as the protective *Lactobacillus* species, is usually lost.

However, culture and PCR do not in any case provide information on the relative quantitative composition of the mucosal flora, i.e. the microbiome. This is only possible through the use of next-generation sequencing (NGS), in which genes from all given microorganisms can be sequenced simultaneously. For this purpose, the microbial gene sequences obtained are compared with extensive databases, which makes it possible to determine the percentage (“abundance”) of individual species.

The Vaginal Microbiome

NGS data obtained from the vaginal microbiome revealed that it is organized into so-called “community state types” (CST) [10]. Among them, four CSTs are dominated by single *Lactobacillus* species: *L. crispatus* (CST I), *L. gasseri* (CST II), *L. iners* (CST III), and *L. jensenii* (CST V). For example, *L. crispatus* dominance is associated with a healthy vaginal microbiome, high production of lactate, and the formation of protective peptides.

CST IV, on the other hand, is characterized by the extensive loss of lactobacilli, with mostly anaerobic bacteria, such as *Gardnerella*, *Atopobium*, *Mobiluncus*, or *Prevotella* being detected in larger or dominating quantities. As a result, the microbiome becomes more diverse, i.e., the lactobacilli disappear or lose their dominance and are replaced by numerous other bacterial species. This increase in diversity can be calculated mathematically and is expressed as alpha diversity or the Shannon index.

In more recent studies, this medically important group is further subdivided into A–C, depending on the predominant constellation of pathogens, although it can be assumed that there are many more subgroups [11, 12] – see ► **Table 1**.

► **Table 1** Differentiation of community state type (CST) IV, according to the “Valencia” classification [11].

CST IV-A: high/moderate relative abundance of <i>G. vaginalis</i> and BVAV1*
CST IV-B: high/moderate relative abundance of <i>G. vaginalis</i> and <i>A. vaginae</i>
CST IV-C: low relative abundance of <i>G. vaginalis</i> , BVAB1*, and <i>Lactobacillus</i> spp., and C0: relatively similar proportion of <i>Prevotella</i> spp. C1: dominated by <i>Streptococcus</i> spp. C2: dominated by <i>Enterococcus</i> spp. C3: dominated by <i>Bifidobacterium</i> spp. C4: dominated by <i>Staphylococcus</i> spp.

* BVAV1: bacterial vaginosis associated bacterium 1

Loss of *Lactobacillus* dominance signals a medically relevant miscolonization or dysbiosis, as group IV is also associated with an altered vaginal pH and an increased Nugent score as an indication of the presence of bacterial vaginosis [10].

CST III is also medically significant because *L. iners* has some peculiarities: it produces only small amounts of lactate and apparently few or no protective peptides. That is why it is also called the “poisoned apple”, which mostly indicates a microbiome in transition: out of or into a dysbiosis or CST IV [13].

The menstrual cycle is considered to be a significant factor in the change of the colonization type: during ovulation, CST stability is the greatest, whereas with menstruation, it decreases the most. In addition, sexual activity is a factor in microbiome change, as is hygiene behavior (alkaline soaps, etc.).

Dysbiotic Factors for Viral Persistence and the Development of CIN Lesions

The previously described association of dysbiosis or BV and HPV infection or cervical intraepithelial neoplasia (CIN) has now been substantiated and clarified by numerous robust NGS studies [6, 14].

Lactobacillus dominance apparently goes hand in hand with natural clearance of HPV. The main species found is *L. crispatus* [15]. In a longitudinal study, *L. gasseri* also showed increased clearance of HPV [16]. A *Lactobacillus*-dominated microbiome also showed a higher likelihood of regression of CIN2 lesions in a follow-up study; slower regression was seen with *Lactobacillus* loss, typically with an increase in BV pathogens [17]. Dominance of *L. crispatus* demonstrated the most rapid regression of CIN lesions [17]. Thus, while *Lactobacilli* are protective, *Gardnerella* and increased microbial diversity are associated with CIN2 progression [18]. *L. iners*, on the other hand, is an exception among *Lactobacilli*: it was found in increased numbers in HPV-positive women and in women with dysplasia [19].

Thus, for both HPV infection and persistence as well as the development and progression of CIN lesions, the vaginal microbiome exhibits a typical pattern similar to that of bacterial vaginosis: Loss of *Lactobacillus* dominance, increased microbial diversity with evidence of typical anaerobic bacteria (CST IV)[17]; in addition,

L. iners (CST III) is associated with the development of CIN lesions [19], possibly also because it indicates a transient microbiome that can cross over into CST IV [13].

Potential Mechanisms of the Vaginal Microbiome in Viral Infection and the Development of CIN Lesions

The complexity of the cervicovaginal microenvironment in HPV infection or CIN lesion is determined not only by the local microbiome but also by its interplay with the patient’s epithelial and immunologic defenses.

Lactobacilli produce numerous protective peptides and metabolites. The focus is on lactic acid (lactate), which is produced by metabolizing glycogen. This inhibits the attachment and growth of pathogenic bacteria, especially BV-associated pathogens [20]. D- or L-lactate isomers are produced; the D-form is mainly produced by *L. crispatus*, *L. jensenii*, and *L. gasseri*, whereas the L-form is produced by *L. iners* and anaerobic pathogens. Thus, in patients with predominant *L. iners* colonization, L-lactate predominates, leading to the activation of metalloproteinase 8 (MMP8) and thereby facilitating the entry of HPV into basal keratinocytes [21]. In contrast, if *L. crispatus* dominates, the viscosity of the cervicovaginal mucus increases, which in turn promotes the attachment of HP viruses [20, 22].


Other factors expressed by *Lactobacilli* to defend against pathogenic bacteria are bacteriocidal and bacteriostatic peptides. Bacteriocin, for example, exerts an inhibitory effect on typical pathogens, especially *Gardnerella vaginalis* [20]. Hydrogen peroxide (H₂O₂) attacks bacteria such as *Prevotella* and *Gardnerella*, which themselves do not produce protective enzymes to degrade this molecule. Such mechanisms thus provide protection of the cervical epithelium and prevent pathogens such as HPV from accessing basal keratinocytes [23].

Due to the decline of *Lactobacilli* with bacterial vaginosis or CST IV, not only do pathogenic anaerobic bacteria become predominant, but the aforementioned defense mechanisms (lactate, bacteriocin, etc.) also stop working. This allows pathogenic microorganisms to colonize the epithelium and promote inflammation through the synthesis of proinflammatory cytokines [24]. In this way, the integrity of the epithelium is damaged and the susceptibility of HPV infection is significantly increased; thus, the persistence of inflammation fosters HPV persistence. When the associated inflammation becomes chronic, this enables the development and persistence of CIN lesions and promotes their progression. In this context, the development of cervical cancer is apparently accompanied by a similar dysbiotic microbiome shift as occurs in the development of CIN lesions [14] – see ► **Fig. 1**.

Towards Individualized Therapy

Microbiome analysis allows not only the detection of a possible dysbiosis, but also helps to determine an individualized therapy.

In cases of severe dysbiosis or bacterial vaginosis, antibiotic therapy is often recommended [25]. This can be modified according to the prevailing spectrum of pathogens (see ► **Fig. 1**).



► **Fig. 1** Schematic representation of the influence of dysbiotic miscolonization on HPV infection, CIN progression and the development of cervical cancer. While the normal Lactobacillus-dominated vaginal microbiome (CST I, II, and V – “eubiosis”) allows clearance of HPV infection, loss of Lactobacillus dominance (CST IV) – and an increase in diversity – or dominance with *L. iners* (CST III) are associated with persistence of HPV, development and progression of CIN lesions, and the development of cervical cancer.

In contrast to classical microbiology, microbiome analysis provides information on the percentage of individual pathogens: hence Gardnerella dominance is treated with different antibiotics than a high abundance of enterococci.

However, antibiotic therapy is associated with a high relapse rate [25]. Administration of *L. crispatus* after antibiotic treatment with metronidazole can significantly reduce the recurrence of bacterial vaginosis [26]. Therefore, restoration or normalization of the vaginal microbiome is considered a promising strategy. The administration of live vaginal lactobacilli (probiotics) has been shown to be effective in the treatment of bacterial vaginosis: longer treatments (1–3 months) have even been shown to be superior to antibiotics in recent meta-analyses [27]. Because *L. iners* indicates a transient microbiome, probiotic stabilization may be advisable in CST III, another individualized, therapeutically useful result of microbiome analysis. Other preclinical studies have demonstrated the anti-tumorigenic effects of probiotics [28]. In addition, there is also clinical evidence that probiotics promote the regression of CIN lesions [29].

Other studies have also demonstrated the efficacy of probiotics. These are mostly carbohydrates that support the growth of beneficial microorganisms in the vagina as selectively as possible. Examples are fructo-oligosaccharides (FOS) or gluco-oligosaccharides (GOS), which promote the growth of lactobacilli, whereas *G. vaginalis* cannot use these sugars as an energy source [30]. Intravaginally administered GOS significantly improved the Nugent score in BV patients after metronidazole administration [23].

An interesting perspective is offered by the administration of lactoferrin, a human peptide secreted on various mucous membranes. This molecule plays an important role in fighting off bacteria as well as numerous viruses. Interestingly, lactoferrin is also active against HPV [31]. An intravaginal application study demonstrated that the composition of the microbiome changes in BV patients: there is a decline in Gardnerella and Prevotella and an increase in Lactobacilli [32].

Indication for Analyzing the Microbiome

From a clinical point of view, there are two main indications for microbiome analysis, the aim being to reduce the cancer risk by restoring the cervicovaginal flora.

The first is a **persistently positive HPV test result**, which is detected during a screening examination with the co-test in women 35 years of age and older, in cases where neither a positive smear test nor a dysplastic or malignant lesion can be detected colposcopically and/or histologically. The goal is to downregulate HPV expression in the epithelium by normalizing (through eubiosis or lactobacillus dominance) the resident bacterial flora and to prevent new infection or the development of dysplastic epithelial changes.

At the same time, it is reasonable to undertake microbiome analysis in cases of HPV-induced **low-grade epithelial lesions or equivocal findings** in women under 35 years of age where surgical treatment by excision (“conization”) is not (yet) indicated. In such cases, the tendency of epithelial lesions to regress is high and current studies suggest that the elimination of existing dysbiosis is likely to have a positive preventive and protective effect. The curtailment of sometimes prolonged HPV persistence in the absence of histo- or cytomorphologic correlates, or the persistence of low-grade HPV-induced epithelial lesions may therefore shorten the surveillance period and the number of repeat colposcopies. This would improve the quality of life of the affected patients and save valuable resources for the healthcare system.

Conclusion

Persistent HPV is a necessary but not sufficient prerequisite for the development of cervical cancer. The dysbiotic shift in the vaginal microbiome appears to be a major co-factor in carcinogenesis. A systematic review of the literature and meta-analysis examined the association between cervicovaginal lactobacilli and genital high-risk HPV infections, CIN, and cervical cancer. Eleven studies with 1230 female patients were evaluated [33]. The results of this meta-analysis confirm the role of lactobacilli in preventing high-risk HPV infection and the resulting cervical preneoplasia and neoplasia.

Analysis of the vaginal microbiome by modern NGS methodology identifies the entire microbial community and the percentages of individual pathogens, which in turn assists with the selection of individualized therapy and may serve as a prophylactic measure against progressive cancerous epithelial transformation.

Conflict of Interest

The authors declare that they have no conflict of interest.

References/Literatur

- [1] Beckmann MW, Stübs FA, Koch MC et al. Diagnosis, therapy and follow-up of cervical cancer. Guideline of the DGGG, DKG and DKH (S3-level, AWMF registry No. 032/O330L, May 2021) – Part 1 with recommendations on epidemiology, screening, diagnostics and therapy. *Geburtshilfe Frauenheilkd* 2022; 82: 139–180. doi:10.1055/a-1671-2158
- [2] Wilting SM, Steenbergen RDM. Molecular events leading to HPV-induced high-grade neoplasia. *Papillomavirus Res* 2016; 2: 85–88. doi:10.1016/j.pvr.2016.04.003
- [3] Plummer M, Schiffman M, Castle PE et al. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. *J Infect Dis* 2007; 195: 1582–1589. doi:10.1086/516784
- [4] Guijon F, Paraskevas M, Rand F et al. Vaginal microbial flora as a cofactor in the pathogenesis of uterine cervical intraepithelial neoplasia. *Int J Gynaecol Obstet* 1992; 37: 185–191. doi:10.1016/0020-7292(92)90379-w
- [5] Mendling W. Die bakterielle Vaginose – nach 60 Jahren immer noch ein Rätsel. *Frauenarzt* 2017; 58: 225–228
- [6] Gillet E, Meys JFA, Verstraelen H et al. Association between bacterial vaginosis and cervical intraepithelial neoplasia: systematic review and meta-analysis. *PLoS One* 2012; 7: e45201. doi:10.1371/journal.pone.0045201
- [7] Liang Y, Chen M, Qin L et al. A meta-analysis of the relationship between vaginal microecology, human papillomavirus infection and cervical intraepithelial neoplasia. *Infect Agent Cancer* 2019; 14: 29. doi:10.1186/s13027-019-0243-8
- [8] Mendling W. Diagnostik und Therapie beim Symptom Fluor. *Frauenarzt* 2018; 59: 120–128
- [9] Curry KD, Wang Q, Nute MG et al. Emu: species-level microbial community profiling of full-length 16S rRNA Oxford Nanopore sequencing data. *Nat Methods* 2022; 19: 845–853. doi:10.1038/s41592-022-01520-4
- [10] Ravel J, Gajer P, Abdo Z et al. Vaginal microbiome of reproductive-age women. *Proc Natl Acad Sci U S A* 2011; 108 (Suppl 1): 4680–4687. doi:10.1073/pnas.1002611107
- [11] France MT, Ma B, Gajer P et al. VALENCIA: a nearest centroid classification method for vaginal microbial communities based on composition. *Microbiome* 2020; 8: 166. doi:10.1186/s40168-020-00934-6
- [12] Symul L, Jeganathan P, Costello EK et al. Sub-communities of the vaginal ecosystem in pregnant and non-pregnant women. *bioRxiv* 2022. doi:10.1101/2021.12.10.471327
- [13] Petrova MI, Reid G, Vanechoutte M et al. Lactobacillus iners: Friend or Foe? *Trends Microbiol* 2017; 25: 182–191. doi:10.1016/j.tim.2016.11.007
- [14] Lin D, Kouzy R, Jaoude JA et al. Microbiome factors in HPV-driven carcinogenesis and cancers. *PLoS Pathog* 2020; 16: e1008524. doi:10.1371/journal.ppat.1008524
- [15] Di Paolo M, Sani C, Clemente AM et al. Characterization of cervico-vaginal microbiota in women developing persistent high-risk human papillomavirus infection. *Sci Rep* 2017; 7: 10200. doi:10.1038/s41598-017-09842-6
- [16] Brotman RM, Shardell MD, Gajer P et al. Interplay between the temporal dynamics of the vaginal microbiota and human papillomavirus detection. *J Infect Dis* 2014; 210: 1723–1733. doi:10.1093/infdis/jiu330
- [17] Mitra A, MacIntyre DA, Lee YS et al. Cervical intraepithelial neoplasia disease progression is associated with increased vaginal microbiome diversity. *Sci Rep* 2015; 5: 16865. doi:10.1038/srep16865
- [18] Usyk M, Zolnik CP, Castle PE et al. Cervicovaginal microbiome and natural history of HPV in a longitudinal study. *PLoS Pathog* 2020; 16: e1008376. doi:10.1371/journal.ppat.1008376
- [19] Piyathilake CJ, Ollberding NJ, Kumar R et al. Cervical microbiota associated with higher grade cervical intraepithelial neoplasia in women infected with high-risk human papillomaviruses. *Cancer Prev Res (Phila)* 2016; 9: 357–366. doi:10.1158/1940-6207.CAPR-15-0350
- [20] Dai W, Du H, Li S et al. Cervicovaginal microbiome factors in clearance of human papillomavirus infection. *Front Oncol* 2021; 11: 722639. doi:10.3389/fonc.2021.722639
- [21] Witkin SS, Mendes-Soares H, Linhares IM et al. Influence of vaginal bacteria and D- and L-lactic acid isomers on vaginal extracellular matrix metalloproteinase inducer: implications for protection against upper genital tract infections. *mBio* 2013; 4: e00460–13. doi:10.1128/mBio.00460-13
- [22] Nunn KL, Wang YY, Harit D et al. Enhanced trapping of HIV-1 by human cervicovaginal mucus is associated with lactobacillus crispatus-dominant microbiota. *mBio* 2015; 6:e01084–15. doi:10.1128/mBio.01084-15
- [23] Mitra A, MacIntyre DA, Marches JR et al. The vaginal microbiota, human papillomavirus infection and cervical intraepithelial neoplasia: what do we know and where are we going next? *Microbiome* 2016; 4: 58. doi:10.1186/s40168-016-0203-0
- [24] Mitchell C, Marrazzo J. Bacterial vaginosis and the cervicovaginal immune response. *Am J Reprod Immunol* 2014; 71: 555–563. doi:10.1111/aji.12264
- [25] Paavonen J, Brunham RC. Bacterial vaginosis and desquamative inflammatory vaginitis. *N Engl J Med* 2018; 379: 2246–2254. doi:10.1056/NEJMra1808418
- [26] Cohen CR, Wierzbicki MR, French AL et al. Randomized trial of lactin-V to prevent recurrence of bacterial vaginosis. *N Engl J Med* 2020; 382: 1906–1915. doi:10.1056/NEJMoa1915254
- [27] Liu HF, Yi N. A systematic review and meta-analysis on the efficacy of probiotics for bacterial vaginosis. *Eur Rev Med Pharmacol Sci* 2022; 26: 90–98. doi:10.26355/eurev_202201_27752
- [28] Jahanshahi M, Dana PM, Badehnoosh B et al. Anti-tumor activities of probiotics in cervical cancer. *J Ovarian Res* 2020; 13: 68. doi:10.1186/s13048-020-00668-x
- [29] Verhoeven V, Renard N, Makar A et al. Probiotics enhance the clearance of human papillomavirus-related cervical lesions: a prospective controlled pilot study. *Eur J Cancer Prev* 2013; 22: 46–51. doi:10.1097/CEJ.0b013e328355ed23
- [30] Rousseau V, Lepargneur JP, Roques C et al. Prebiotic effects of oligosaccharides on selected vaginal lactobacilli and pathogenic microorganisms. *Anaerobe* 2005; 11: 145–153. doi:10.1016/j.anaerobe.2004.12.002
- [31] Mistry N, Drobni P, Näslund J et al. The anti-papillomavirus activity of human and bovine lactoferricin. *Antiviral Res* 2007; 75: 258–265. doi:10.1016/j.antiviral.2007.03.012
- [32] Pino A, Giunta G, Randazzo CL et al. Bacterial biota of women with bacterial vaginosis treated with lactoferrin: an open prospective randomized trial. *Microb Ecol Health Dis* 2017; 28: 1357417. doi:10.1080/16512235.2017.1357417
- [33] Wang H, Ma Y, Li R et al. Associations of cervicovaginal lactobacilli with high-risk human papillomavirus infection, cervical intraepithelial neoplasia, and cancer: A systematic review and meta-analysis. *J Infect Dis* 2019; 220: 1243–1254. doi:10.1093/infdis/jiz325